A consortium of longevity and immunology experts surveys recent advances in immunotherapies that selectively eliminate senescent cells. They detail CAR T strategies against uPAR and NKG2D ligands, senolytic vaccines targeting GPNMB or CD153, and PD-1/PD-L1 blockade, highlighting mechanisms and preclinical rejuvenation benefits.
Key points
uPAR-directed CAR T cells safely eliminate uPAR+ senescent cells, reversing fibrosis and improving metabolism in mice.
NKG2D-CAR T constructs recognize NKG2D ligands on stress-induced senescent cells, demonstrating efficacy in aged mice and nonhuman primates without off-target toxicity.
PD-1/PD-L1 immune checkpoint blockade reduces PD-L1+ senescent cell accumulation and alleviates multiple age-related phenotypes via CD8+ T cell activation.
Why it matters:
Immunotherapeutic senolytics promise targeted clearance of aging cells, offering safer, more durable rejuvenation therapies compared to conventional drugs.
Q&A
What are senescent cells?
How do senolytic CAR T cells work?
What is a senolytic vaccine?
Why target PD-L1 in aging?
Read full article
Academy
Cellular Senescence and Immunosenescence
Overview: As we age, many of our cells enter a permanent state of cell cycle arrest called senescence. Rather than functioning normally or dying, these senescent cells release inflammatory and tissue-degrading factors—the senescence-associated secretory phenotype (SASP)—which drive chronic inflammation, impair tissue repair, and promote age-related diseases. Immunosenescence refers to age-related declines in the immune system, reducing its ability to clear senescent cells and fight infections or cancer.
Key Features of Senescent Cells
- Cell cycle arrest: Senescent cells cannot divide, halting DNA replication as a tumor-suppressive mechanism.
- SASP secretion: Inflammatory cytokines, chemokines, growth factors, and proteases that disrupt local tissue environments.
- Resistance to apoptosis: Activation of anti-apoptotic pathways (SCAPs), making them hard to eliminate naturally.
- Surface markers: Senescent cells express unique proteins such as uPAR, NKG2D ligands, PD-L1, GPNMB, CD153, which allow targeted therapies to distinguish them from healthy cells.
Immune System Interactions
In a healthy young body, immune cells (natural killer cells, macrophages, T cells) patrol tissues, recognize, and clear emerging senescent cells. As immunosenescence progresses, immune surveillance weakens: fewer naive T cells are generated by an involuted thymus, immune checkpoint pathways (PD-1/PD-L1) can be upregulated on senescent cells, and chronic inflammation (inflammaging) further exhausts immune function.
Immunological Senolytics
Researchers are developing immunotherapies to selectively remove senescent cells, capitalizing on their distinct markers:
- CAR T Cells: T cells engineered with chimeric antigen receptors (CARs) to target uPAR or NKG2D ligands. Once infused, these CAR T cells bind and kill senescent cells, reducing fibrotic scarring and restoring organ function in preclinical models.
- Senolytic Vaccines: Vaccines against antigens like CD153 and GPNMB induce antibody responses that label senescent cells for destruction by natural immune processes (e.g., antibody-dependent cell-mediated cytotoxicity).
- Immune Checkpoint Blockade: Antibodies blocking PD-1/PD-L1 reawaken exhausted T cells, enhancing natural clearance of PD-L1+ senescent cells and improving age-related tissue function.
Benefits and Challenges
Benefits: Immunosenolytics can be highly specific, sparing healthy cells; memory T cells may provide durable protection; vaccines are scalable and cost-effective. Challenges: Senescent cell heterogeneity demands multiple targets; balancing removal of detrimental senescent cells with preserving beneficial ones (e.g., in wound healing); avoiding excessive immune activation (cytokine release syndrome) in therapies like CAR T.
Outlook in Longevity Science
Immunological senolytics represent a promising frontier in longevity research. By harnessing and guiding the body’s own defense mechanisms, these approaches aim to safely clear senescent cells, reduce inflammation, and rejuvenate multiple organs. Future work will refine target selection, optimize delivery, and translate preclinical successes into clinical trials to combat aging and age-related diseases.